Veru Pivots Sabizabulin to Pancreatic Cancer After Preclinical Win Over Daraxonrasib Resistance
VERU sits 37% above its 52-week low of $2.05 on light trading volume (0.4× avg).
Summary
Veru announced positive preclinical data showing sabizabulin overcomes resistance to Revolution Medicines' daraxonrasib in KRAS-driven pancreatic cancer cell lines, with an IC50 of 18.2nM. The company will advance sabizabulin into a planned Phase 2b trial for metastatic pancreatic cancer after daraxonrasib failure, and will discontinue its development for atherosclerotic cardiovascular disease. This follows the 8-K filed today and the recent ATM offering and going concern warning; the pivot refocuses the pipeline on a high-unmet-need oncology indication. A pre-IND meeting with the FDA is planned for Q4 2026.
At the time of this announcement, VERU was trading at $2.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45M. The 52-week trading range was $2.05 to $7.33. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.